Company: NIVFW
Filing Date: 2025-09-18
Form Type: F-1
Source: 0001213900-25-088927
Chunk: 243

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-18
Form: F-1
Chunk 243
---
 Seller. Any tax liabilities in Kyrgyzstan arising from the transfer of these
balances shall be borne by the Buyer.

The following table summarizes
the financial impact of the disposal:

| ● | Consideration received: Cash of $11 |

| ● | Net assets acquired of $486,706 |

| ● | Reversal of excess tax of $486,706 |

The disposal was accounted
for in accordance with ASC 810, Consolidation. As a result, the Company deconsolidated First Fertility Bishkek LLC and recognized a write
back of tax (after netting against the cash consideration received) in the amount of US$ in the consolidated statements of operations
for the year ended December 31, 2024.

The disposal did not represent
a strategic shift and, therefore, was not classified as a discontinued operation under ASC 205-20.

NOTE 21 — BUSINESS ACQUISITION

On December 17, 2024, the
Company acquired Bi Clinic Ltd (“Bi Clinic”), which holds a license for the provision of IVF treatment, surrogacy, and ancillary
caring services, for total consideration of $. The acquisition enhances the Company’s position in healthcare fertility sector.
The transaction was accounted for as a business combination under ASC 805, Business Combinations.

At the acquisition date,
Bi Clinic had not yet commenced revenue-generating activities but had established the necessary regulatory approvals and licensing framework
to operate as an IVF and surrogacy service provider. These approvals, along with the Company’s planned integration of medical personnel
and operational processes, provide the necessary inputs and substantive processes required to meet the definition of a business under
ASC 805.

Since Bi Clinic had no other
assets or liabilities, the entire purchase price was allocated to intangible assets, specifically the IVF license and regulatory approvals.
No goodwill was recognized in connection with the transaction.

As Bi Clinic had no prior
operations, its financial results have been included in the consolidated financial statements from the acquisition date, with no historical
revenue or expenses impacting the Company’s consolidated results. Pro forma financial information has been omitted, as the acquisition
is not considered material to the Company’s financial results.

NOTE 22 — SUBSEQUENT EVENTS

The Company evaluated subsequent
events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon
this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment or
disc